# The preclinical amyloid sensitive composite to determine subtle cognitive differences in preclinical Alzheimer’s disease

## Abstract

Recently, the focus of Alzheimer’s disease (AD) research has shifted from the clinical stage to the preclinical stage. We, therefore, aimed to develop a cognitive composite score that can detect the subtle cognitive differences between the amyloid positive (Aβ+) and negative (Aβ−) status in cognitively normal (CN) participants. A total of 423 CN participants with Aβ positron emission tomography images were recruited. The multiple-indicators multiple-causes model found the latent mean difference between the Aβ+ and Aβ− groups in the domains of verbal memory, visual memory, and executive functions. The multivariate analysis of covariance (MANCOVA) showed that the Aβ+ group performed worse in tests related to the verbal and visual delayed recall, semantic verbal fluency, and inhibition of cognitive inference within the three cognitive domains. The Preclinical Amyloid Sensitive Composite (PASC) model we developed using the result of MANCOVA and the MMSE presented a good fit with the data. The accuracy of the PASC score when applied with age, sex, education, and APOE ε4 for distinguishing between Aβ+ and Aβ− was adequate (AUC = 0.764; 95% CI = 0.667–0.860) in the external validation set (N = 179). We conclude that the PASC can eventually contribute to facilitating more prevention trials in preclinical AD.

## Introduction

With the advancement of amyloid-β (Aβ) positron emission tomography (PET), the focus of research on Alzheimer's disease (AD) has shifted from the clinical and symptomatic stages to the preclinical and asymptomatic stages of AD1. Consequently, approximately 20–30% of cognitively normal (CN) elderly population appear to be CN individuals with Aβ positivity2,3,4. These CN individuals with elevated amyloidosis are considered to be more vulnerable to AD progression. This can be demonstrated by the subtle cognitive difference between CN individuals with amyloid positivity and those without Aβ biomarkers in the late preclinical stage5. Furthermore, several reports have claimed that approximately 25% of Aβ+ CN individuals converts to mild cognitive impairments (MCI) or dementia in approximately 3 years6,7.

Although Aβ PET has such advantage of early detection of Aβ+ biomarker, it is usually challenging to obtain a large number of participants with PET data due to the high cost and safety concerns. However, the importance of Aβ biomarker has kept rising as several prevention trials are currently being conducted in preclinical AD with the expectation to target Aβ. Thus, it will be pragmatic and essential for clinicians to predict who might be at high risk of having an Aβ+ biomarker without the help of neuroimaging techniques. As a result, we need to, instead, investigate the distinct neuropsychological features of CN who have elevated Aβ, which may help clinicians predict preclinical AD by reducing screen failures and monitoring the therapeutic efficacy of prevention.

Previously, there were several attempts to investigate the distinct neuropsychological features of Aβ+ CN individuals. However, the results were inconsistent among studies to date. Multiple studies have consistently reported that high amyloid burden in CN adults is associated with poorer performance in episodic memory8,9. On the other hand, a large lifespan study of CN adults found association of amyloid deposition with executive functions, but not with memory burden10. This discrepancy may be because not many previous studies considered the effects of measurement errors, although there is always a possibility for the presence of measurement errors in psychometrics11. In fact, there was a study considered measurement errors using structural equation modeling (SEM) to examine the associations between amyloid burden or white matter hyperintensity and cognition9. However, there are still few studies considering the effects of measurement errors in studying biomarkers and cognition together, and there is a need to build more evidence for this methodology in this regard. Accordingly, we used the multiple-indicators multiple-causes (MIMIC) model in our study to examine Aβ related cognitive functions. By using the principle of factor analysis, the MIMIC model can control for these measurement errors to estimate the latent values. That is, MIMIC may empower a composite model to sensitively detect subtle cognitive differences between Aβ+ and Aβ− in CN elderlies. However, to our knowledge, no Aβ+ CN studies have yet applied this factor structure method to develop a cognitive composite model for identifying preclinical AD in the elderly population.

In the present study, we aimed to determine if there are any distinct cognitive domains and cognitive measures of Aβ+ CN using the MIMIC model, which may yield lower background noise in measurements. We also developed the Preclinical Amyloid Sensitive Composite (PASC) model, a composite model that precisely distinguishes cognitive differences between Aβ+ and Aβ− in CN individuals. Then, we computed the PASC score employing the PASC model we developed. Finally, we validated the PASC score along with age, sex, education, and APOE ε4 to distinguish between Aβ+ and Aβ− CN in an external validation set. Considering that subtle deficits in episodic memory and executive functions appear to be critical in preclinical AD due to their strong association with AD progression12, we hypothesized that the PASC score consisting of memory and executive functions might differentiate Aβ+ CN from Aβ− CN with adequate accuracy.

## Results

### Demographic characteristics of participants

The demographic and neuropsychological characteristics of the study participants are presented in Table 1. The overall mean age of the participants was 69.9 years. Among the 423 participants, 75 were Aβ+ (17.7%). The frequency of APOE ε4 carriers was 24.6%. The Aβ+ group was significantly older than the Aβ− group (71.5 ± 6.8 years vs. 69.5 ± 8.4 years, p < 0.05). The Aβ+ group also displayed a higher percentage of APOE ε4 carriers compared with the Aβ− group (58.0% vs. 17.5%, p < 0.001). However, the two groups did not significantly differ in education level and proportion of female participants.

### MIMIC model for latent mean analysis

The confirmatory factor analysis (CFA) model was successfully validated to control measurement errors. Accordingly, error covariance was added between the residual variances associated with the Seoul Verbal Learning Test-Elderly’s version (SVLT-E) immediate and delayed recalls and the Rey-Osterrieth Complex Figure Test (RCFT) immediate and delayed recalls. The CFA model with added error covariance fit the data well (χ2 = 212.181, df = 78, p < 0.001; RMSEA = 0.064; CFI = 0.957; TLI = 0.942; SRMR = 0.056). All factor loadings in the model were significant between 0.49 and 0.89. Next, a latent mean difference between Aβ+ and Aβ− for each cognitive domain was verified. The latent mean model fit the data well (χ2 = 359.481, df = 128, p < 0.001; RMSEA = 0.065; CFI = 0.944; TLI = 0.919; SRMR = 0.048). The result revealed that the differences between the Aβ+ and Aβ− groups in attention, visuospatial function, and language function were not significant, but the latent means in the Aβ+ group were significantly lower than the Aβ− group in the three domains of verbal memory, visual memory, and executive functions (Table 2).

### MANCOVA

Based on the results above, further statistical analyses were conducted for each neuropsychological assessment within the episodic memory and executive functions. Multivariate analysis of covariance (MANCOVA) was used to see the score differences of the tests under episodic memory and executive functions between the Aβ+ and Aβ− groups when sex, education, and age were controlled. The result of the MANCOVA is shown in Table 3. Few neuropsychological subtests showed meaningful differences between the groups. Primarily, we set the level of significance at 0.1. Regarding episodic memory, the SVLT-E delayed recall showed a difference in score between the Aβ+ and Aβ− groups (F(1, 418) = 3.666, p = 0.056). For the RCFT, the Aβ+ group performed worse, not only on the delayed recall (F(1, 418) = 4.036, p = 0.045), but also on the immediate recall (F(1,418) = 2.898, p = 0.089). However, due to the extremely high correlation between the two subtests (r = 0.935), we considered that it would be reasonable to use only one subset in our composite model. Based on the clinical and statistical significance, the RCFT delayed recall was favored over the RCFT immediate recall for the PASC. In terms of executive functions, the Korean-Color Word Stroop test (K-CWST) color reading (F(1, 418) = 4.745, p = 0.030) and the Controlled Oral Word Association Test (COWAT) animal naming showed worse performance in the Aβ+ group compared to that in the Aβ− group (F(1, 418) = 3.152, p = 0.077).

### Development of the preclinical amyloid sensitive composite (PASC) model

Based on the MANCOVA results and the literature, the following 5 tests were finally selected: the SVLT-E delayed recall; the RCFT delayed recall; the K-CWST color reading; the COWAT animal naming; and the Korean Mini-Mental State Examination (K-MMSE). The K-MMSE was added for examining global cognition. The PASC CFA model presented a good fit with the data (χ2 = 4.757, df = 5, p = 0.933; RMSEA < 0.001; CFI = 1.000; TLI = 1.001; SRMR = 0.014). All factor loadings in the model were significant between 0.56 and 0.73 (Fig. 1). The MIMIC model was used to ensure that the PASC distinguished between Aβ+ and Aβ− (Fig. 2). Our MIMIC model for the PASC fit the data well (χ2 = 56.526, df = 21, p < 0.001; RMSEA = 0.063; CFI = 0.955; TLI = 0.936; SRMR = 0.036). The result showed that the latent mean in the Aβ+ group was significantly lower than the Aβ− group (t = -2.340, p = 0.019) (Table 4).

### Calculation of the PASC score

In order to create the composite score, we implemented the principal component analysis (PCA) with the z-scores of the 5 tests. As a result, the following composite equation was generated:

$${\text{PASC}} = .70\left( {SVLT delayed z} \right) + .61\left( {RCFT delayed z} \right) + .67\left( {Stroop CR z} \right) + .55\left( {COWAT animal z} \right) + .58\left( {MMSE z} \right)$$

The receiver operating characteristic (ROC) curve analysis presented a decent accuracy for the PASC score when applied with age, sex, education, and APOE ε4 to distinguish between Aβ+ and Aβ− (AUC = 0.771; 95% CI = 0.704–0.837) (Fig. 3a, Table 5). The sensitivity (71%) and specificity (73.5%) were optimal for distinguishing between Aβ+ and Aβ−, and the Youden index was 0.445.

### External validation

The demographic and neuropsychological features of the validation sample are described in Table 1. The overall mean age of the validation set was comparable with that of the development set (69.4 ± 8.2 years vs. 69.9 ± 8.1, p = 0.494). Similarly, the years of education in the validation set were not different from those in the development set (12.0 ± 4.4 vs. 11.8 ± 4.8, p = 0.527). The proportion of female in the validation sample also did not differ from that in the development sample (60.3% vs. 63.1%, p = 0.519). Moreover, the rate of Aβ+ of the validation sample was similar to that of the development sample (16.2% vs. 17.7%, p = 0.650). The proportion of APOE ε4 carriers in the validation set was also at comparable levels to that in the development set (22.8% vs. 24.6%, p = 0.648). Within the validation sample, the Aβ+ group was significantly older than the Aβ− group (73.7 years vs. 68.6 years, p < 0.05). The Aβ+ group also displayed a higher percentage of APOE ε4 carriers compared with the Aβ− group (51.9% vs. 17.1%, p < 0.001). However, the two groups did not significantly differ in education level and proportion of female participants. The PASC CFA model exhibited a good fit with the validation sample (χ2 = 2.338, df = 5, p = 0.801; RMSEA < 0.001; CFI = 1.000; TLI = 1.028; SRMR = 0.016). The MIMIC model for the PASC showed a fair fit to the validation sample (χ2 = 49.870, df = 21, p < 0.001; RMSEA = 0.088; CFI = 0.917; TLI = 0.882; SRMR = 0.051). The accuracy of the PASC score when applied with age, sex, education, and APOE ε4 for distinguishing between Aβ+ and Aβ− was adequate (AUC = 0.764; 95% CI = 0.667–0.860). The sensitivity and specificity were also optimal when the Youden index was 0.402 (sensitivity = 70.4%; specificity = 69.8%) (Fig. 3b, Table 5). The results of the ROC curve analysis in the external validation set were comparable to those in the development set (Table 5).

## Discussion

We investigated the distinct neuropsychological features of Aβ+ CN elderlies in a carefully phenotyped, CN cohort that underwent detailed neuropsychological tests, MRI, and amyloid PET scans with the standardized protocols. Accordingly, there were several significant neuropsychological findings in this study. First, the MIMIC model found the latent mean difference between the Aβ+ and Aβ− groups in the domains of verbal memory, visual memory, and executive functions. Furthermore, MANCOVA showed that the Aβ+ group performed worse in the SVLT-E delayed recall, the RCFT delayed recall, the K-CWST color reading, and the COWAT animal naming within the three cognitive domains. The PASC model that we developed using the result of MANCOVA and the MMSE presented a good fit with the data. Finally, the accuracy of the PASC score when applied with age, sex, education, and APOE ε4 for distinguishing between Aβ+ and Aβ− was adequate (AUC = 0.764; 95% CI = 0.667–0.860) in the external validation set (N = 179). Our results, therefore, suggested that the PASC might contribute to decreasing financial loss due to screen failures in preclinical AD clinical trials and facilitating more prevention trials subsequently.

The demographic profile of our participants was extremely close to that of the previously reported Asian society profile. The CN Aβ+ percentage in Asian countries is known to be lower than that in western countries. The percentage of CN amyloid positivity in the Asian population ranged between 18 and 25% according to the Korean Brain Aging Study for the Elderly Diagnosis and Prediction of Alzheimer’s disease (KBASE) and Japanese ADNI (J-ADNI)13,14. On the other hand, the western population, represented by ADNI, was reported to range approximately from 25 to 45% Aβ positivity rate15,16. Our study exhibited approximately 18% Aβ positivity in the 423 CN individuals, which was in line with that in the Asian population. The discrepancy between our results and that of the western society may be explained by the differences in the frequency of APOE ε4 and the age of the study participants. Our cohort seemed to have a lower percentage of APOE ε4 (23%) than that reported by ADNI (27%)17. Moreover, the younger age of our cohort (mean, 69.9 years) compared to that of the ADNI CN individuals (mean, 75.8 years) may have affected the lower rate of amyloid positivity17. Regardless of these disparities, the APOE ε4 rate and the age of our cohort were still at comparable levels to J-ADNI’s APOE ε4 rate (24%) and CN individuals’ ages (mean, 67.9)13.

Our major finding was that the Aβ+ CN individuals presented a lower performance in verbal memory, visual memory, and executive functions compared to Aβ− CN, which was generally consistent with the findings of previous meta-analyses. In terms of memory, there has been a consensus that episodic memory has a strong association with Aβ burden18,19,20. In our study, delayed recall task of both verbal and visual memory tests especially stood out as the performance difference between Aβ+ and Aβ− seem to be more prominent than immediate or recognition tasks. This result is not surprising because previous studies with CN or MCI also suggested that using delayed recall may be good predictor of Aβ positivity21,22. Unlike episodic memory, the results regarding executive functions in the previous studies are not entirely consistent. A recent meta-analysis suggested a significant difference in executive function19, while two others showed either a small effect size or a weak association with Aβ burden18,20. This may be because the previous studies did not consider the effects of measurement errors that could impact the individual test scores. However, applying a factor analysis with the latent variables, we controlled for the measurement errors from each test score for more precise measurement of the corresponding cognitive function.

In the present study, we also developed the PASC that is sensitive to the subtle cognitive differences in CN based on amyloid positivity. The PASC comprises the SVLT-E delayed recall, the RCFT delayed recall, the COWAT animal naming, and the K-CWST color reading, which were found to be significantly different between the two CN groups from the three cognitive domains, and the K-MMSE. We included the K-MMSE in the PASC because the Mini-Mental State Exam (MMSE) is a practical neuropsychological test to examine individual cognitive function holistically23. Global cognition was previously reported to be associated with amyloidosis7,24,25,26, and has been considered to help with early identification of dementia risk and further cognitive decline27. Furthermore, other composite scores such as the Preclinical Alzheimer Cognitive Composite (PACC) and the Alzheimer’s Prevention Initiative Composite Cognitive Test Score (APCC) include the MMSE for global functioning and orientation status28,29,30. In this regard, we included the MMSE for the convenience of harmonization in the future international collaboration. In fact, the PASC may seem similar to the PACC29. However, the PACC has been mainly applied to track cognitive changes in preclinical AD over time25,31, whereas the PASC investigated the cognitive difference between Aβ+ CN and Aβ− CN cross-sectionally.

Although AD pathology progression involves the deterioration of multiple cognitive domains, there are a few benefits to observe cognitive differences in CN individuals with a single composite that is a unidimensional outcome. First, it allows comprehensive yet precise cognitive assessment particularly in preclinical AD. Currently, the MMSE23 and the Clinical Dementia Rating (CDR)32 are commonly used to assess individual cognitive function holistically. However, they often display ceiling effects in CN individuals33,34. Therefore, they are not quite sensitive measures for CN individuals. Furthermore, the ratings of the CDR primarily rely on clinicians’ judgments following patient and caregiver interviews. In other words, bias is rarely avoidable in the CDR. As a result, there is a need for a novel and reliable measure to holistically assess cognitive function specific to preclinical AD, and we expect that the PASC can meet the need. Another advantage of obtaining a unidimensional composite is that it induces a more precise result in the outcome measurement. Compared to using multi-outcomes, using a single outcome usually yields lower background noise in the measurement, which derives a lower risk of Type-I error11,28. Therefore, applying a single primary outcome has better reliability and sensitivity especially in terms of detecting subtle cognitive differences in preclinical AD.

The major strength of our study is that we considered measurement errors in the test scores when we implemented the analyses. Another strength is the large sample size of the CN cohort who underwent amyloid PET. In spite of these strengths, there are a few limitations to our study. First, the participants went through different types of PET ligands. The variety of the tracers may have affected the visual reads of amyloid deposition. However, this limitation can be somewhat alleviated by the high correlations among the different ligands35,36. Second, we did not explore the clinical effects of the PASC. Future studies with clinical impacts of the PASC on other biomarkers like tau or cortical atrophy may be recommended. Another limitation is that our study used dichotomized variable of amyloid burden. The issue about dichotomization of amyloid deposition has been constantly questioned as there were several studies showing longitudinal cognitive decline related to subthreshold amyloid in Aβ− CN individuals37,38,39. In future studies, continuous measure of amyloid burden may be used to embrace the issue of subthreshold amyloid. Also, longitudinal studies using the PASC may be needed to examine the clinical applicability related to the issue.

Our study created the PASC which is a sensitive cognitive composite score for Aβ+ in CN elderly individuals, subsequent to investigating some distinct cognitive features of Aβ+ in CN elderly individuals. The PASC, which employed significant tests in episodic memory and executive functions, along with the global cognitive measure of the K-MMSE, showed adequate accuracy when it was applied with age, sex, education, and APOE ε4. Therefore, we expect the PASC to be applied potentially into diverse forms of studies such as trial ready registries40,41 and to contribute to decreasing financial loss due to screen failures and facilitating more prevention trials subsequently. Moreover, given that the cognitive tests that reflect the characteristics of early preclinical AD are anticipated to reflect the later cognitive change, we expect the PASC to be used for monitoring of disease progression or therapeutic efficacy.

## Methods

### Study participants

A total of 423 CN participants were recruited from September 2015 to December 2018 at the Samsung Medical Center in Seoul, South Korea. All the participants met the following criteria to be qualified as CN: (a) the K-MMSE 24 or above -1.5 standard deviation (SD) from the age-, sex-, and education-adjusted norms if the education period was less than 9 years; (b) above -1 SD from the age-, sex-, and education-adjusted norms on the delayed recall of the SVLT-E; (c) above -2 SD from the age-, sex-, and education-adjusted norms on the Korean version of the Boston Naming Test (K-BNT), the RCFT copy, and the K-CWST color reading; and (d) an absence of other neurological disorders. The screenings were conducted by trained clinicians and neuropsychologists. Brain MRI confirmed the absence of structural lesions, including territorial cerebral infarction, brain tumors, hippocampal sclerosis, vascular malformation, and cerebral amyloid angiopathy (CAA).

The external validation sample involved 91 CN participants who were recruited from December 2018 to April 2020 at the Samsung Medical Center and 88 CN participants who were recruited from May 2017 to April 2020 at Gangnam Severance Hospital. None of the participants in the external validation sample was included in the original study sample.

Written informed consents were obtained from each participant. This study was approved by the Institutional Review Board at the Samsung Medical Center. All methods were implemented in accordance with the approved guidelines.

### 18F-labeled amyloid PET acquisition and analysis

A total of 423 CN participants underwent 18F-labelled amyloid PET; 219 underwent 18F-florbetaben PET, 203 underwent 18F-flutemetamol PET, and 1 underwent 18F- florbetapir PET scanning at the Samsung Medical Center. The scanning was performed using a Discovery Ste PET/CT scanner (GE Medical Systems, Milwaukee, WI, USA) with a 3D scanning mode that examined 47 slices of 3.3 mm thickness spanning the entire brain. Prior to a 20-min emission PET scan with dynamic mode consisting of 4 × 5 min frames, 311.5 MBq 18F-florbetaben, 197.7 MBq 18F-flutemetamol, and 370 MBq 18F-florbetapir were injected. The scan was performed 90 min after the injection. 3D PET images were reconstructed in a 128 × 128 × 48 matrix with a 2 × 2 × 3.27 mm voxel size using the ordered-subsets expectation–maximization algorithm (18F-florbetaben, iteration = 4 and subset = 20; 18F-flutemetamol, iteration = 4 and subset = 20; 18F-florbetapir, iteration = 4 and subset = 16).

Visual assessment was done by three experienced raters (two nuclear medicine doctors and one neurologist) who were blinded to patient information, and the assessment was dichotomized as Aβ+ or Aβ− using visual reads. The visual assessments for 18F-florbetaben PET, 18F-flutemetamol PET, and 18F-florbetapir PET were performed with the scoring system that was used in the previous studies42,43,44,45,46. Inter-rater agreement was excellent for both FBB (Fleiss k = 0.86) and for FMM (Fleiss k = 0.78). After the raters individually rated, we determined the final visual positivity based on the majority visual reading result. Also, both FBB and FMM showed the high concordance rates between visual assessment and SUVR cutoff categorization for Aβ deposit (93.5% in FBB and 91.6% in FMM). The raters had successfully completed the electronic training program provided by the manufacturer to be qualified for the visual assessment.

### Neuropsychological assessments

The second edition of the Seoul Neuropsychological Screening Battery (SNSB-II) was administered to all the participants to assess their cognitive functions47,48. The SNSB-II was standardized on 1,067 CN elderly individuals in South Korea48. The normative data for the individual neuropsychological test was established based on a representative of South Korean population with age between 45 and 90 and the education level over 18 years. In our study, we used the following tests that are included in the SNSB-II: Digit Span Test (DST) forward and backward for attention; the K-BNT for language; the Clock Drawing Test (CDT) and the RCFT for visuospatial function and visual memory; the SVLT-E for verbal memory; and phonemic and semantic COWAT, K-CWST, Digit Symbol Coding (DSC), and the Korean Trail Making Test-Elderly’s version (K-TMT-E) for executive functions. The RCFT involved copying, immediate recall, 20-min delayed recall, and recognition tests. Similarly, the SVLT-E was composed of immediate recall trials, delayed recall, and recognition tests. In addition to the tests mentioned above, the K-MMSE was also used for the global mental state assessments of the participants49.

### Statistical analyses

Demographic characteristics were compared between the Aβ+ and Aβ− groups using the independent sample t-test if the variables were continuous and the chi-square test if the variables were categorical.

CFA was yielded to validate the structure of the five cognitive domains. CFA is one of the multiple forms of SEM, which confirms whether a pre-specified factor structure fits the data well11. We validated the CFA model for the neuropsychological test battery to control for measurement errors. The tests included in each cognitive domain were the same as those described earlier, and the language domain consisted of a single test score. The subtests of the SVLT-E and the RCFT in the memory domain were measured respectively using the same method. Therefore, it was considered acceptable to add an error covariance between the residual variances associated with the SVLT-E immediate and delayed recalls and the RCFT immediate and delayed recalls. Since our factor structure included both reflective and causal indicators, we used the MIMIC model to compare the latent means in the cognitive domains between the Aβ+ and Aβ− groups (Fig. 4).

MANCOVA was performed to see if any neuropsychological tests showed a significant difference between the two groups. Since the measurement errors were not treated in the MANCOVA, we deliberately set the cutoff for significance to be less conservative in order to increase the power and reduce the risk of type II errors. Thus, the tests with p-value < 0.1 were selected to be included in the composite model. The MIMIC model was repeated to identify whether these tests were sensitive to differences between Aβ+ and Aβ− in CN elderlies as a composite. For the PASC score equation, the PCA was used to obtain the weight for each test score. Accuracy, sensitivity, and specificity of the PASC score combined with age, sex, education, and APOE ε4 for distinguishing between Aβ+ and Aβ− were tested by ROC analysis.

The CFA and the MIMIC models of the PASC were validated in the cross-validation sample. The accuracy for distinguishing between Aβ+ and Aβ− of the PASC score combined with age, sex, education, and APOE ε4 was investigated by the ROC curve analysis in the external validation sample.

Raw score of each test was used in the statistical analyses for development of the PASC model. Z-scores were used to compute the PASC score. The K-TMT-E part B was log-transformed for accuracy of the estimate due to its large range (0–300) and non-normality. Multiple imputation and full information maximum likelihood estimations were used to treat missing values.

IBM SPSS (version 25.0, SPSS Statistics/IBM Corp, Armonk NY, USA) was used for the statistical analyses. For comparisons of latent means between the groups, maximum likelihood estimation was analyzed by Mplus (version 8.0)50. However, due to the violation of normality, bias-corrected bootstraps were performed together.

## References

1. 1.

Dubois, B. et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement.12, 292–323. https://doi.org/10.1016/j.jalz.2016.02.002 (2016).

2. 2.

Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA313, 1924–1938. https://doi.org/10.1001/jama.2015.4668 (2015).

3. 3.

Kern, S. et al. Prevalence of preclinical Alzheimer disease: comparison of current classification systems. Neurology90, e1682–e1691. https://doi.org/10.1212/WNL.0000000000005476 (2018).

4. 4.

Rowe, C. C. et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging31, 1275–1283. https://doi.org/10.1016/j.neurobiolaging.2010.04.007 (2010).

5. 5.

Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement.7, 280–292. https://doi.org/10.1016/j.jalz.2011.03.003 (2011).

6. 6.

Rowe, C. C. et al. Predicting Alzheimer disease with beta-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann. Neurol.74, 905–913. https://doi.org/10.1002/ana.24040 (2013).

7. 7.

Villemagne, V. L. et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann. Neurol.69, 181–192. https://doi.org/10.1002/ana.22248 (2011).

8. 8.

Bischof, G. N., Rodrigue, K. M., Kennedy, K. M., Devous, M. D. Sr. & Park, D. C. Amyloid deposition in younger adults is linked to episodic memory performance. Neurology87, 2562–2566. https://doi.org/10.1212/WNL.0000000000003425 (2016).

9. 9.

Hedden, T. et al. Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. J. Neurosci.32, 16233–16242. https://doi.org/10.1523/JNEUROSCI.2462-12.2012 (2012).

10. 10.

Rodrigue, K. M. et al. β-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology78, 387–395. https://doi.org/10.1212/WNL.0b013e318245d295 (2012).

11. 11.

Fayers, P. M. & Machin, D. Quality of Life the Assessment, Analysis, and Reporting of Patient-Reported Outcomes 3rd edn. (Wiley, London, 2016).

12. 12.

Blacker, D. et al. Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch. Neurol.64, 862–871. https://doi.org/10.1001/archneur.64.6.862 (2007).

13. 13.

Iwatsubo, T. et al. Japanese and North American Alzheimer’s disease neuroimaging initiative studies: harmonization for international trials. Alzheimers Dement.14, 1077–1087. https://doi.org/10.1016/j.jalz.2018.03.009 (2018).

14. 14.

Hwang, J. et al. Clinical and biomarker characteristics according to clinical spectrum of Alzheimer’s disease (AD) in the validation Cohort of Korean Brain Aging study for the early diagnosis and prediction of AD. J. Clin. Med. https://doi.org/10.3390/jcm8030341 (2019).

15. 15.

Landau, S. M. et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol.72, 578–586. https://doi.org/10.1002/ana.23650 (2012).

16. 16.

Ewers, M. et al. CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex22, 1993–2004. https://doi.org/10.1093/cercor/bhr271 (2012).

17. 17.

Petersen, R. C. et al. Alzheimer’s disease neuroimaging initiative (ADNI): clinical characterization. Neurology74, 201–209. https://doi.org/10.1212/WNL.0b013e3181cb3e25 (2010).

18. 18.

Baker, J. E. et al. Cognitive impairment and decline in cognitively normal older adults with high amyloid-beta: a meta-analysis. Alzheimers Dement. (Amst)6, 108–121. https://doi.org/10.1016/j.dadm.2016.09.002 (2017).

19. 19.

Duke Han, S., Nguyen, C. P., Stricker, N. H. & Nation, D. A. Detectable neuropsychological differences in early preclinical Alzheimer’s disease: a meta-analysis. Neuropsychol. Rev.27, 305–325. https://doi.org/10.1007/s11065-017-9345-5 (2017).

20. 20.

Hedden, T., Oh, H., Younger, A. P. & Patel, T. A. Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology80, 1341–1348. https://doi.org/10.1212/WNL.0b013e31828ab35d (2013).

21. 21.

Kandel, B. M. et al. Neuropsychological testing predicts cerebrospinal fluid amyloid-β in mild cognitive impairment. J. Alzheimer’s Dis. JAD46, 901–912. https://doi.org/10.3233/jad-142943 (2015).

22. 22.

Palmqvist, S. et al. Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer’s disease: cross-validation study of practical algorithms. Alzheimer’s Dement. 15, 194–204. https://doi.org/10.1016/j.jalz.2018.08.014 (2019).

23. 23.

Folstein, M. F., Folstein, S. E. & McHugh, P. R. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198. https://doi.org/10.1016/0022-3956(75)90026-6 (1975).

24. 24.

Ossenkoppele, R. et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA313, 1939–1949. https://doi.org/10.1001/jama.2015.4669 (2015).

25. 25.

Donohue, M. C. et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA317, 2305–2316. https://doi.org/10.1001/jama.2017.6669 (2017).

26. 26.

Petersen, R. C. et al. Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol.73, 85–92. https://doi.org/10.1001/jamaneurol.2015.3098 (2016).

27. 27.

Blumenthal, J. A. et al. Lifestyle and neurocognition in older adults with cardiovascular risk factors and cognitive impairment. Psychosom. Med.79, 719–727. https://doi.org/10.1097/psy.0000000000000474 (2017).

28. 28.

Ayutyanont, N. et al. The Alzheimer’s prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer’s disease treatments in presenilin 1 E280A mutation carriers. J. Clin. Psychiatry75, 652–660. https://doi.org/10.4088/JCP.13m08927 (2014).

29. 29.

Donohue, M. C. et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol.71, 961–970. https://doi.org/10.1001/jamaneurol.2014.803 (2014).

30. 30.

Weintraub, S. et al. Measuring cognition and function in the preclinical stage of Alzheimer’s disease. Alzheimer’s Dement. Transl. Res. Clin. Interv. 4, 64–75. https://doi.org/10.1016/j.trci.2018.01.003 (2018).

31. 31.

Insel, P. S. et al. Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology93, e322–e333. https://doi.org/10.1212/wnl.0000000000007831 (2019).

32. 32.

Morris, J. C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology43, 2412–2414. https://doi.org/10.1212/wnl.43.11.2412-a (1993).

33. 33.

Samtani, M. N., Raghavan, N., Novak, G., Nandy, P. & Narayan, V. A. Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer’s subjects from the Alzheimer’s Disease Neuroimaging Initiative. Neuropsychiatr. Dis. Treat.10, 929–952. https://doi.org/10.2147/NDT.S62323 (2014).

34. 34.

Spencer, R. J. et al. Psychometric limitations of the mini-mental state examination among nondemented older adults: an evaluation of neurocognitive and magnetic resonance imaging correlates. Exp. Aging Res.39, 382–397. https://doi.org/10.1080/0361073x.2013.808109 (2013).

35. 35.

Johnson, K. A. et al. Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the society of nuclear medicine and molecular imaging, and the Alzheimer’s Association. Alzheimers Dement.9, e-1-16. https://doi.org/10.1016/j.jalz.2013.01.002 (2013).

36. 36.

Landau, S. M. et al. Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers. Eur. J. Nucl. Med. Mol. Imaging41, 1398–1407. https://doi.org/10.1007/s00259-014-2753-3 (2014).

37. 37.

Bischof, G. N. & Jacobs, H. I. L. Subthreshold amyloid and its biological and clinical meaning: long way ahead. Neurology93, 72–79. https://doi.org/10.1212/wnl.0000000000007747 (2019).

38. 38.

Farrell, M. E. et al. Regional amyloid accumulation and cognitive decline in initially amyloid-negative adults. Neurology91, e1809–e1821. https://doi.org/10.1212/WNL.0000000000006469 (2018).

39. 39.

Farrell, M. E. et al. Association of longitudinal cognitive decline with amyloid burden in middle-aged and older adults: evidence for a dose–response relationship. JAMA neurology74, 830–838. https://doi.org/10.1001/jamaneurol.2017.0892 (2017).

40. 40.

Aisen, P. et al. Registries and Cohorts to Accelerate Early Phase Alzheimer's Trials. A Report from the E.U./U.S. Clinical Trials in Alzheimer's Disease Task Force. J. Prev. Alzheimers Dis3, 68–74, https://doi.org/10.14283/jpad.2016.97 (2016).

41. 41.

Cummings, J. et al. Re-engineering alzheimer clinical trials: global Alzheimer’s platform network. J. Prev. Alzheimers Dis.3, 114–120. https://doi.org/10.14283/jpad.2016.93 (2016).

42. 42.

Clark, C. M. et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA305, 275–283. https://doi.org/10.1001/jama.2010.2008 (2011).

43. 43.

Farrar, G. Regional visual read inspection of [18F]flutemetamol brain images from end-of-life and amnestic MCI subjects. J. Nucl. Med.58, 1250 (2017).

44. 44.

Johnson, K. A. et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement.9, S72-83. https://doi.org/10.1016/j.jalz.2012.10.007 (2013).

45. 45.

Kim, H. J. et al. 18F-AV-1451 PET imaging in three patients with probable cerebral amyloid angiopathy. J. Alzheimers Dis57, 711–716. https://doi.org/10.3233/JAD-161139 (2017).

46. 46.

Martínez, G. et al. 18F PET with flutemetamol for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst. Rev.2017, CD012884. https://doi.org/10.1002/14651858.CD012884 (2017).

47. 47.

Kang, S. H. et al. The cortical neuroanatomy related to specific neuropsychological deficits in Alzheimer’s continuum. Dement. Neurocogn. Disord.18, 77–95. https://doi.org/10.12779/dnd.2019.18.3.77 (2019).

48. 48.

Kang, Y., Jahng, S. & Na, D. L. Seoul Neuropsychological Screening Battery. Second Edition (SNSB-II): Professional Manual (Human brain research & consulting co, Incheon, 2012).

49. 49.

Kang, Y. A normative study of the Korean-Mini mental state examination (K-MMSE) in the Elderly. Korean J. Psychol.25, 1–12 (2006).

50. 50.

Muthen, L. K. & Muthen, B. Mplus User's Guide : Statistical Analysis with Latent Variables. (Muthén & Muthén, 2017).

## Acknowledgements

This research was supported by a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI19C1132), a fund (2018-ER6203-02) by Research of Korea Centers for Disease Control and Prevention, the Brain Research Program of the National Research Foundation (NRF) funded by the Ministry of Science & ICT (NRF-2018M3C7A1056512), the National Research Foundation of Korea(NRF) grant funded by the Korea government(MSIT) (NRF-2019R1A5A2027340), and the National Research Council of Science & Technology (NST) grant by the Korea government (MSIP) (No. CRC-15-04-KIST).

## Author information

Authors

### Contributions

Conception and design of the study were done by A.H., Y.J.K, J.C., and S.W.S. Acquisition of data was done by A.H., Y.J.K., H.J.K., H.J., D.L.N., J.C., and S.W.S. Data Analysis were done by A.H. and Y.J.K. Interpretation of the data were done by A.H., Y.J.K, J.C., and S.W.S. Development of external validation set and advice on revised paper were done by H.C., S.H.C., B.C.K., and K.W.P. Drafting and revising the manuscript for content were done by A.H., Y.J.K, J.C., and S.W.S. Lastly, J.C. and S.W.S. confirmed the final approval of the manuscript. A.H. and Y.J.K. are the co-first authors of this article and equally contributed to the manuscript. J.C. and S.W.S are the joint corresponding authors of this article.

### Corresponding authors

Correspondence to Juhee Chin or Sang Won Seo.

## Ethics declarations

### Competing interests

The authors declare no competing interests.

### Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Rights and permissions

Reprints and Permissions

Hahn, A., Kim, Y.J., Kim, H.J. et al. The preclinical amyloid sensitive composite to determine subtle cognitive differences in preclinical Alzheimer’s disease. Sci Rep 10, 13583 (2020). https://doi.org/10.1038/s41598-020-70386-3

• Accepted:

• Published: